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Abstract
The Effects of Dihydrobiopterin and Tetrahydrobiopterin on Hydrogen Peroxide and
Nitric Oxide Release during Extracorporeal Shockwave Lithotripsy (ESWL)
ESWL is an effective, non-invasive therapy utilized to fragment stones in the
kidney and subsequently be cleared in the urinary tract. Although lithotripsy provides a
safer alternative to invasive treatments for removing stones, ESWL may cause
vasoconstriction after ESWL treatment, reducing renal blood flow, which can cause
kidney damage leading to acute to chronic hypertension clinically. This may be due to
kidney vascular endothelial dysfunction, which is characterized as increased oxidative
stress and decreased endothelial nitric oxide synthase (eNOS)-derived nitric oxide (NO)
bioavailability. We hypothesized that ESWL would decrease NO and increase hydrogen
peroxide (H2O2) in rat renal veins. Rats given tetrahydrobiopterin (BH4), the essential
cofactor of eNOS coupling, would cause a decrease in H2O2 release and increase in NO
release compared to ESWL + saline controls. On the contrary, when dihydrobiopterin
(BH2), the cofactor for eNOS uncoupling, is given at the end of ESWL treatment we
predict an increase in H2O2 release and decrease in NO release compared to ESWL +
saline controls. Blood NO and H2O2 were directly measured in real-time by inserting a
microsensor into the left renal vein in the anesthetized rat. ESWL treatment consisted of
1,000 shocks for approximately 13 minutes. Saline or drug was injected via the jugular
vein immediately post-ESWL and at the same time point for the non-ESWL controls.
ESWL + saline controls (n = 5; p< 0.01) had significantly increased H2O2 release
compared to the non-ESWL controls (n = 5) and NO release in ESWL + saline rats (n =
5; p< 0.01) was significantly decreased compared to non-ESWL controls (n = 6) from 5-
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30 mins post-ESWL. In ESWL+BH4 rats (n=5), H2O2 released was significantly reduced
from 10-30 mins compared to ESWL + saline controls (p≤ 0.05). ESWL+BH4 (n=5) also
significantly increased NO release 5-30 mins compared to ESWL + saline controls (p≤
0.01). For both NO (n=5) and H2O2 (n=5) release, the ESWL + BH2 group showed a
similar decrease in NO and increase in H2O2 release to the ESWL + saline group (n=5).
This may be because eNOS could be under saturated conditions with respect to BH2
levels generated by ESWL. The data shows that BH4 significantly reduces H2O2 and
increases NO, thereby promoting eNOS coupling.

This results in increased NO

bioavailability and decreased oxidative stress on the renal microvasculature.
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Introduction
The kidneys are essential organs in the human body for maintaining homeostasis
by regulating blood pressure, maintaining pH and filtering toxic by-products from the

blood. Urinary calculi, or stones located in the kidney or ureter, can pose potentially lifethreatening problems and urologists are faced with the issue of how to effectively and
safely remove these kidney stones. Extracorporeal shock wave therapy (ESWL) is an
effective, non-invasive, clinical treatment for kidney stones. ESWL treatment is used to
fragment stones located in the kidney or ureter. ESWL is the treatment of choice for
many urologists because of its low morbidity, high success rate and less-invasive nature
as compared to an invasive surgical approach (You et al. 2010; Childs et al. 2011). A
lithotripter breaks down kidney stones by focusing high-intensity, acoustic pulses through
a lens and propagates these shockwaves in the area of the stone, in turn breaking up the
stone. After treatment, the fragmented pieces, which are less that 1mm in diameter, are
passed with the flow of the urinary tract.
Although lithotripsy provides a safer treatment option for removing the harmful
stones, the problem that arises is that to break up the kidney stone, it requires many
repetitive shockwaves that not only hit the kidney stone but also hit the surrounding renal
tissue. These forces used to fragment the stone can cause underlying damage to the renal
vascular endothelium, which may not be easily detected. Furthermore, ESWL not only
causes damage by the physical forces of the shockwaves, but also through increased
oxidative stress indirectly from the shockwaves. ESWL may cause prolonged
vasoconstriction after ESWL treatment, reducing renal blood flow, increasing leukocyteendothelial interactions, and subsequent endothelial dysfunction, which may cause
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kidney damage leading to acute to chronic hypertension clinically. A 19-year follow-up
ESWL study showed that a subpopulation developed hypertension (Krambeck et al.
2006). There is a lack of research examining the pharmacotherapeutics that can be used
to treat this endothelial dysfunction caused by ESWL. As a result, this current study

investigates how this endothelial dysfunction can be decreased which may regain normal
kidney function by using pharmacological therapy to reduce the release of superoxide
(SO) and subsequent hydrogen peroxide (H2O2) release in blood by promoting
endothelial nitric oxide synthase (eNOS) coupling with tetrahydrobiopterin (BH4).
ESWL Treatment: Limitations and Improvements
In the past three decades, there has been significant evolution in the clinical
management of kidney stones, and the trend has gone away from surgical treatment
options to minimally invasive procedures, such as shockwave lithotripsy (Childs et al.
2011). Since the introduction of lithotripsy in the 1980s, it has been regarded as the
primary treatment option for the treatment of kidney stones, but this does not mean that it
does not come without its limitations (Gillitzer et al. 2009). One of the limitations of
shockwave lithotripsy is the size and composition of the kidney stone. Taking into
account the capacity of the kidney and ureter to clear debris, shockwave treatment is only
recommended for kidney stones that are smaller that 1-2 cm. Furthermore, shockwave
treatment is not recommended in cases of kidney stones with unfavorable composition,
such as cysteine, brushite and calcium oxalate monohydrate (Childs et al. 2001; Gillitzer
et al. 2009). Other factors besides stone size and composition that are shown to affect
stone fragmentation by lithotripsy are the location of the stone, the stone’s radiodensity,
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the patient’s body mass index, and the degree of hydronephrosis, or swelling due to
increased water inside the kidney (You et al. 2010).
Kidney stones treated with shockwave lithotripsy are mainly comminuted, or
broken up, by two mechanisms. The first force is from a positive pressure wave, where
the actual shockwave, or stress wave, acts in a hammer-like action to cause stone
fragmentation at both ends of the stone. The second force is from cavitation, where
negative pressure waves cause the expansion and collapse of cavitation bubbles in the

fluid surrounding the stone (Rassweiler et al. 2011). Stress waves and cavitation bubbles
have shown to work in a synergistic manner to accomplish stone fragmentation. Stress
waves initiate the fragmentation at low output voltages, but higher-energy shockwaves
are needed to create the cavitation bubbles and to overcome the scattering effect
(Maloney et al. 2006). The scattering effect in lithotripsy is where fine fragments gather
around the remaining stone and scatter the subsequent shockwaves, and this is overcome
by increasing the shockwave intensity, which maintains the stone fragmentation (You et
al. 2010). In order to maximize the efficiency of shockwave lithotripsy, you need the
optimal combination of the intensity, number and rate of shockwaves that causes the least
amount of tissue injury while also causing the most stone fragmentation, all while using a
minimal amount of energy. If other factors remain constant, the degree of stone
fragmentation increases proportionally to the number and intensity of shockwaves, but
unfortunately, the degree of renal tissue injury also increases proportionally to the
shockwave dose and rate (You et al. 2010).
Although shockwave lithotripsy is regarded as the first-line option and most
commonly performed procedure for stone treatment, especially those stones located in the
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upper urinary tract, it does cause acute injury that has been reported to lead to long-term
complications (McAteer and Evan 2008). Research has shown that ESWL causes acute

renal injury in most patients who receive a large enough shockwave dose to break-up the
kidney stone. This renal injury is mostly vasculature injury whereby the shockwaves
caused lesions and ruptured blood vessels in the kidney, which can cause hemorrhage
into the renal tissue. Moreover, if severe enough, this parenchymal bleeding can cause
subcapsular hematomas or even lead to renal failure in some cases (Connors et al. 2009).
Studies have shown that vascular lesion size and the volume of hemorraghic tissue in the
kidney increases proportionally to the number of shockwaves given and the shockwave
intensity (McAteer and Evan 2008). Furthermore, cavitation bubbles are also believed to
play a role in the vascular injury that occurs from ESWL treatment. When cavitation
bubbles collapse, they create a fluid micro-jet that delivers a significant force to a small
area. If one of these cavitation bubbles were to expand and collapse inside of a blood
vessel, the force of the generated micro-jet would possibly be able to rupture the blood
vessel (McAteer and Evan 2008).
These acute injuries to the renal vasculature from shockwave lithotripsy, although
not directly proven to be the definite cause of chronic hypertensive disease, have been of
serious concern to lead to long-term complications. Possible chronic complications from
ESWL, especially in patients that have received multiple lithotripsy treatments, include
new-onset hypertension, diabetes mellitus, and the exacerbation of stone disease
(McAteer and Evan et al. 2008).
Ongoing research has examined the ESWL protocol to determine parameters that
set the highest efficacy while making patient safety the main concern. In order to
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determine the safest and most efficient protocol, researchers have investigated ESWL

factors including the number of shockwaves, the frequency of the shockwaves delivered,
the voltage output of the lithotripter, step-wise treatment versus constant energy output,
and pretreatment shockwaves. Ultimately, the goal is to completely break up the kidney
stone so that it can be passed through the urinary tract, all while causing the least amount
of renal damage by delivering the least amount of shockwaves with the lowest energy
output at the lowest rate of administration.
The results of the ongoing research have yielded many beneficial changes to the
standard ESWL protocol. One study using animal models has shown that ESWL damage
to the kidney is dose-dependent. The damage to the kidney increased with the number of
shockwaves delivered, and the high-amplitude shockwaves proved to be more damaging
than the lower-amplitude shockwaves (Patterson et al. 2002). Furthermore, the findings
of this study have shown that trauma to the kidney from ESWL treatment is significantly
reduced at a slow rate of shockwave administration (30 shockwaves/min), and that it also
significantly increased stone comminution compared to the conventional ESWL rate of
delivery (120 shockwaves/min) (Patterson et al. 2002). A second study showed that
while delivering shockwaves at a rate of 30 shockwaves per minute may be timeconsuming and unrealistic in a clinical setting. A comparison of shockwave frequencies
of 60 shockwaves per minute versus 120 shockwaves per minute still showed improved
stone comminution at 60 shockwaves per minute, which would provide a more realistic
clinical alternative (Gillitzer et al. 2008). Knowing the improved stone comminution at
60 shockwaves per minute and how it is a more realistic clinical treatment option than
delivering at a rate of 30 shockwaves per minute, a third study assessed the renal
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response to treating with ESWL at a rate of 60 shockwaves per minute. The results from
this study showed significantly reduced size of the acute hemorrhagic lesion in the
kidneys treated at a rate of 60 shockwaves per minute compared to those treated at 120
shockwaves per minute (Connors et al. 2009).
In addition to studies on ESWL frequency, there has been ongoing research
investigating the effect of output voltage distribution on stone comminution efficiency.
Two studies have both proven that a progressive increase in lithotripter output voltage
generates the greatest stone comminution efficiency compared to a constant or decreasing
output voltage during ESWL treatment (You et al. 2010; Maloney et al. 2006). The
mechanism behind the efficiency of increased voltage output is that in the beginning of
ESWL the stress waves initiate stone fragmentation at low output voltages. In the later
part of ESWL therapy, the higher output voltages will increase cavitation activity and
also overcome the scattering effect caused by the collection of fine stone particles
surrounding the remaining kidney stone (Maloney et al. 2006).
Lastly, one study has shown that “pretreatment” with shockwaves at a low energy
output can protect the kidney from injury from subsequent higher energy shockwaves.
The study proved that pretreatment with as little as 100 shockwaves at 12 kilovolts (kV)
prior to treatment of 2,000 shockwaves at 24 kV on the same area significantly reduced
the size of the lesion. Although the mechanism for this protective effect from
pretreatment is not fully understood, an analysis of renal hemodynamics in this study
have shown that shockwaves produce transient vasoconstriction in the kidney, and this
increased vascular tone during pretreatment may make the vessels less susceptible to
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damage, such as vessel rupture, during the subsequent high energy shockwaves (McAteer
and Evan 2008).
Using these studies, researchers were able to develop a new ESWL treatment
protocol that generates more effective stone comminution with less injury to the kidney
itself. This new protocol called for a slower rate of shockwave administration with 60
shockwaves per minute instead of 120 shockwaves per minute, using as little shockwaves
as necessary with a progressively increasing energy output from 12 kilovolts (kV) as the
priming dosage to 24 kV during the ESWL treatment (McAteer and Evan 2008).
However, despite the adopted changes to the ESWL protocol that yields significantly
reduced injury to the kidney, our lab has produced research showing that oxidative stress
is increased post-ESWL treatment. Our recent study has shown that ESWL generates
increases in H2O2 and decreases in NO release levels similar to an ischemia-reperfusion
(I/R) injury and characteristic of eNOS dysfunction. Although ESWL treatment is not a
true representation of an I/R event where a complete loss of blood perfusion occurs
during ischemia, oxidative stress occurs as a result of ESWL. ESWL shockwaves cause
localized areas of tissue ischemia in the kidney, which are susceptible to free radical
generation during reperfusion, when ESWL treatment is ceased and blood flow is
restored to these areas. Our ESWL protocol is similar to one used by Weber et al (1992)
in rats that consists of 1000 shockwaves total. The first 500 shockwaves are delivered at
a rate of 60 shockwaves/minute followed by 500 shockwaves at 120 shockwaves/minute
(Weber et al. 1992). Other studies suggest that ESWL induces oxidative stress and
decreased NO bioavailability.

8

	
  

This increase in oxidative stress post-ESWL has led our lab to investigate the role
of eNOS during oxidative stress caused by ESWL treatment, and we aimed to decrease
this oxidative stress by manipulating eNOS regulation pharmacotherapeutically.
Hopefully, treatment of the oxidative stress to the renal vasculature endothelium will be
crucial to diminish or prevent the acute injuries that occur during ESWL treatment
leading to long-term complications in the kidney.
Endothelium and Nitric Oxide
Vascular endothelium is the layer of cells that lines the entire circulatory system,
and creates a crucial barrier between the circulating blood and the vessel wall. The
endothelium is important since it provides a physical barrier between blood and tissue
and maintains vascular homeostasis. The endothelial cells form a semi-permeable barrier
between the blood vessel lumen and the surrounding tissue, and they are able to control
the transfer of molecules into and out of the circulating bloodstream. The endothelium
also plays a role in blood clotting, as it provides an anti-thrombotic surface, but
inflammation can initiate when it becomes dysfunctional. Furthermore, the vascular
endothelium is able to control blood pressure by regulating vasoconstriction and
vasodilatation. The endothelial cells can release vasodilators, such as nitric oxide (NO),
which serves as a primary vasodilator and causes smooth muscle relaxation. In addition
to vasodilatation and smooth muscle relaxation, NO is a critical regulator of multiple
aspects of homeostasis in the cardiovascular system, including blood pressure,
inflammation and platelet activation (Channon 2004). Furthermore, NO is a pivotal
molecule in the regulation of blood flow and tissue oxygenation, and NO affects oxygen
supply and demand in two ways. The first aspect is that NO regulates vascular tone and
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blood flow by activating soluble guanylate cyclase in the vascular smooth muscle, and
the second aspect is that it controls mitochondrial oxygen consumption by inhibiting
cytochrome c oxidase (Chen et al. 2008). The loss of NO bioavailability from the
vascular endothelium is a major characteristic of endothelial dysfunction, which causes
various vascular diseases including hypertension, diabetes and atherosclerosis (Channon
2004). An impaired endothelial-dependent vasorelaxation is seen in these disease states,
and this is associated with an increased oxidative vascular damage. Research has
proposed that alteration in the levels of both nitric oxide and superoxide are responsible
for endothelial dysfunction that leads to these vascular diseases (Vasquez-Vivar et al.
1998).

The Structure and Function of eNOS
eNOS is the primary producer of NO in the vascular endothelium that lines the
cardiovascular system. NO produced from eNOS in the vascular endothelium is known
to be the key source of NO for regulating vasorelaxation. eNOS, also known as NOS3, is
one of three isoforms of nitric oxide synthase (NOS) that have been identified, and the
other two isoforms are neuronal NOS (nNOS) and inducible NOS (iNOS). Both eNOS
and nNOS are constitutively expressed and controlled by the availability of intracellular
calcium and calmodulin, whereas iNOS is upregulated principally in leukocytes in
chronic disease states and releases micromolar amounts of NO (Chen et al. 2008;
Vasquez-Vivar et al. 2003).
eNOS is primarily located within caveolae located on the endothelium surface.
This enzyme consists of two identical monomer units, and they consist of a flavin-
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containing reductase domain and a heme-containing oxygenase domain, which contains a
prosthetic heme group and a binding site for BH4 and dihydrobiopterin (BH2) molecules,
and they are connected together by a calcium/calmodulin binding peptide. Upon the
calcium/calmodulin binding, electrons from NADPH are transferred from the reductase
domain to the oxygenase domain, whereby eNOS becomes activated (Vasquez-Vivar et
al. 2003). eNOS is a cytochrome p450 reductase-like enzyme that catalyzes the electron
flow from NADPH through the flavin adenine dinucleotide (FAD) and flavin
mononucleotide (FMN) and then transferred to the oxidase domain of the other monomer
to a prosthetic heme group, where the oxidation of L-arginine occurs (Cai and Harrison
2000).
An important aspect of proper eNOS function is the necessity of the BH4 cofactor.
BH4 binds on the oxygenase domain adjacent to the heme active site. There is one
binding site for BH4 on the oxygenase domain of each monomer, so in total there are two
BH4 molecules on each eNOS homodimer (Alp and Channon 2004). The location at
which the BH4 cofactor binds at the interface between the two monomers is important to
maintain the functional configuration of the enzyme because it provides stability of the
homodimer through numerous hydrogen bonds. Along with the stabilization of the eNOS
dimer, BH4 is also a major component in the oxidation of L-arginine to its intermediate
N-hydroxyl-L-arginine followed by the oxidation of the intermediate to produce NO and
L-citrulline (Raman et al. 1998). This entire reaction depends on the electron flow from
NADPH to FAD to FMN and lastly to the oxygen molecule, located on heme-iron group
forming a ferrous-dioxygen complex.
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eNOS Coupling and Uncoupling

It has been well established that under normal conditions endothelial-derived NO
is produced from eNOS when BH4 is the cofactor, and this process is referred to as eNOS
coupling. In the coupled state with BH4 as the cofactor, the electron flow is generated
through NADPH to FAD to FMN to the oxygenase domain, and this is “coupled” with
the oxidation of the guanadino nitrogen of L-arginine in the presence of molecular
oxygen to produce L-citrulline and NO. (See Figure 1a) The BH4 cofactor is needed to
aid in the coupling of the L-arginine substrate and the heme site of the eNOS oxygenase
domain (Chen et al. 2010). By contrast, when the electron transfer within the active site
becomes “uncoupled” from L-arginine oxidation, eNOS uses the molecular oxygen as a
substrate to generate SO instead of NO (Chen et al. 2010). (See Figure 1b) This process
is known as eNOS uncoupling and occurs when BH2 is the predominant cofactor.
Subsequently, SO is further converted to hydrogen peroxide (H2O2) by superoxide
dismutase (SOD) (Perkins et al. 2012). It is well known that H2O2 is a good indicator or
oxidative stress, and it has a longer half-life (i.e. minutes) compared to SO (i.e. seconds),
which makes it easier to measure (Chen et al. 2010). BH4 and BH2 bind to eNOS with
equal affinity, therefore the relative ratio between these two cofactors determines the
principal product from eNOS.
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Figure 1. Schematic Diagram of eNOS Coupling and Uncoupling.
When BH4 is the eNOS cofactor, it binds to the heme oxygenase domain to promote
the binding of the L-arginine substrate. (Left of figure) In the coupled state, the
electron flow is “coupled” to the oxidation of L-arginine in the presence of
molecular oxygen to produce L-citrulline and NO. (Right of figure) By contrast
when BH4 is oxidized to BH2 or when the BH2/BH4 ratio is increased, the process
becomes uncoupled and L-arginine does not bind to eNOS and uncoupled oxygen
accepts the electron to produce superoxide. Adopted from Chen et al. 2010.
BH4 is susceptible to oxidation by reactive oxygen species to form BH2. There are
several mechanisms that produce reactive oxygen species but the main sources that
produce SO are NADPH oxidases, mitochondrial respiration, and uncoupled eNOS.
NADPH oxidases are upregulated in certain cardiovascular risk factors such as
hypertension or in conditions of exacerbated oxidative stress. (Bertolet et al. 2013).
Additional oxidation of BH4 can come from incomplete oxidative phosphorylation in
mitochondria dysfunction. The mitochondrial electron transport chain is the predominant
source of SO in cells going through normal respiration, and a SO molecule is needed for
the initial oxidation of BH4 to BH2. The Crabtree et al (2008) study concluded that
mitochondrion-derived SO plays a role in BH4 oxidation, by showing that BH4 oxidation
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was significantly decreased by selective inhibitors of mitochondrial electron transport
complexes I or II. Their findings implicate a role for mitochondrion-derived SO BH4
oxidation, leading to eNOS uncoupling. (Crabtree et al. 2008; Perkins et al. 2012).

Finally, and increased BH2/BH4 ratio causes BH2 to become the eNOS cofactor to
stimulate eNOS uncoupling, which is a main producer of SO (Alp and Channon 2004). It
is well known that BH2 and BH4 bind to the oxygenase domain of eNOS with equal
affinity, so when the BH2/BH4 ratio is increased, BH2 can easily displace BH4 to become
the eNOS cofactor (Chen et al. 2010) (See Figure 2). Another likely mechanism for the
continued oxidation of BH4 is caused by an interaction with peroxynitrite, which is
generated from the interaction between NO and SO to produce peroxynitrite anion
(ONOO-). This leads to a perpetual cycle when superoxide in the endothelium scavenges
the NO to produce ONOO-, which will then oxidize BH4 to BH2. The BH2:BH4 ratio will
increase and cause eNOS uncoupling, and this further produces SO to quench the NO and
continues to promote vascular oxidative stress (Alp and Channon 2004).
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Figure 2. BH4/BH2 ratio controls NO and SO generation from eNOS.
The augmentation of BH4 via supplementation or synthesis will increase the
production of NO by promoting eNOS coupling. By contrast, low BH4 levels or an
increase in BH2 will promote eNOS uncoupling and lead to an increase in SO
generation. Adapted from Vasquez-Vivar et al. 2002.
BH4 is synthesized from three pathways: de novo biosynthesis pathway, salvage
pathway and de novo regeneration pathway. In the de novo biosynthesis pathway, BH4 is
synthesized from guanosine triphosphate (GTP) by GTP cyclohydrolase I, which is the
rate limiting step in this pathway, to d-erythro-7,8-dihydroneopterin triphosphate, which
is then converted to 6-pyruvoyl-tetrahydropterin by 6-pyruvoyl-tetrahydropterin synthase.
Lastly is it converted to BH4 by sepiapterin reductase through NADPH-dependent
reductions. In the salvage pathway, non-enzymatic sepiapterin is converted to BH2 by
sepiapterin reductase, and BH2 is then reduced to BH4 by dihydrofolate reductase
(Seungkyoung et al. 2006).

BH4 and BH2
It has been well established that a decrease in endothelial-derived NO and an
increase in SO are the key factors leading to vascular endothelial dysfunction. There are
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several factors that contribute to the loss of NO bioavailability during endothelial
dysfunction, including reduced NO synthesis and NO scavenging by reactive oxygen
species, such as SO, which increases the oxidative stress by forming ONOO- (Alp and

Channon 2004). Current research has shown that the eNOS cofactors, BH4 and BH2, are
intertwined with the levels of NO and SO released from the endothelium due to eNOS
coupling and uncoupling, respectively. Vasquez-Vivar et al. (2002) have produced
research showing that the presence or absence of eNOS cofactor BH4 critically controls
the release of NO and SO, respectively. Thus, supplementation with BH4 will prevent the
accumulation of reactive oxygen species and promote the production of NO. On the
other hand, supplementation with BH2, the oxidized form of BH4, will promote the
production of SO. Lastly, they claim that elevating BH4 levels via supplementation is
crucial to saturate eNOS that is deficient in BH4 or to compete with BH2 for the eNOS
binding site to decrease SO formation and increase NO generation (Vasquez-Vivar et al.
2002).
A study by Crabtree et al. (2008) showed the clinical relevance of the BH4/BH2
ratio on endothelial function by assessing the flow-mediated vasodilatation (FMD) in the
brachial artery. Their results showed that there was a significant positive correlation
between FMD and BH4, a negative relationship between FMD and BH2, and
subsequently a significant positive relationship between FMD and the BH4/BH2 ratio.
Also, their results indicated that plasma BH2 levels increased, whereas levels of BH4
remained unchanged, in association with the increment number of various coronary risks
factors that the patients in the study had.
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Furthermore, our lab has also conducted research in the past using BH4 and BH2
to attenuate or exacerbate endothelial dysfunction caused by a true I/R injury in femoral
and myocardial I/R models (Chen et al. 2010). The results from the Chen et al. study
(2010) showed BH4 increased NO release from the endothelium in a dose-dependent
manner by promoting eNOS coupling, and H2O2, the marker for oxidative stress, was
significantly decreased and this data correlates with improved post-reperfused cardiac
function. By contrast, BH2 lead to decreased NO bioavailability, which was due BH2
promoting eNOS uncoupling to produce SO instead of NO, further quenching NO due to
the formation of ONOO-. This data correlated with compromised post-reperfused cardiac
function (Chen et al. 2010) and suggested that by administering BH4 at the start of
reperfusion to maintain eNOS coupling would help attenuate the oxidative stress that
leads to vascular endothelial dysfunction. It is our hope that by administering BH4 and
BH2 after ESWL treatment we will see similar results in NO and H2O2 release in the
kidney vasculature as was seen in the hind limb I/R model, and this could lead us on the
right tract to be able to attenuate the vascular damage caused by ESWL treatment for
kidney stones.
Previous studies by this lab using this ESWL model have investigated the effects
of ESWL on NO and H2O2 levels and experimented with regulation from protein kinase
C epsilon (PKC-ε), which is expressed in the endothelium and positively regulates eNOS
activity by phosphorylation (Iames et al. 2011). Specifically, last year Iames et al. (2011)
explored the effects of PKC-ε regulation through PKC-ε activator and inhibitor peptides
on ESWL-induced oxidative stress. The PKC-ε activator and inhibitor peptides regulate
eNOS by either facilitating or inhibiting the translocation of PKC-ε to the cell membrane,
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respectively, which promotes or inhibits PKC-ε phosphorylation of the cell member
substrates, such as eNOS (Iames et al. 2011; Zhang et al. 2005). The study results
indicated that PKC-ε inhibitor significantly attenuated the ESWL-induced effects on

H2O2 increase and NO decrease, and the data suggesed that these beneficial effects were
from the inhibition of uncoupled eNOS activity (Iames et al. 2011). Furthermore, PKC-ε
activator was similar to ESWL-saline controls that showed increased H2O2 and decreased
NO release compared to no-ESWL controls. The Iames et al. (2011) study suggested that
inhibiting eNOS uncoupling reduced oxidative stress in ESWL and was consistent with
the hypothesis in this study.
In this study, we will again test the effects of ESWL on NO and H2O2 release to
confirm ESWL-induced oxidative stress. We will also explore the effects of regulating
eNOS coupling and uncoupling with the supplementation BH4 and BH2, respectively, on
levels of NO and H2O2 in an attempt to decrease endothelial dysfunction after ESWL
treatment.
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Hypothesis

This project will study the effects of ESWL on the levels of H2O2 and NO release
from vascular endothelium of the left renal vein. Furthermore, the project will focus on
the changes in H2O2 and NO release after infusion with BH2 or BH4 to facilitate eNOS
uncoupling or coupling, respectively under ESWL treatments.

Effects of ESWL on H2O2 and NO Release Compared to Non-ESWL Controls
The induction of ESWL treatment on saline controls (ESWL + saline) will
decrease NO release and increase H2O2 release compared to saline controls that did not
receive ESWL treatment (no-ESWL + saline). The stress from the acoustic shockwaves
generated by ESWL will damage the renal endothelium and increase oxidative stress.
This is turn will stimulate the production of H2O2 and decrease NO bioavailability. The
no-ESWL control group will provide a baseline level of blood H2O2 or NO release for
which the other experimental groups can compare.

Effects of BH4 on H2O2 and NO Release
We hypothesized that the infusion of BH4 post-ESWL treatment (ESWL + BH4)
would cause less of a decrease in NO bioavailability compared to ESWL + saline
controls. Furthermore, infusion of BH4 post-ESWL will decrease the release of H2O2
compared to ESWL + saline controls. This hypothesis suggests that administration of
BH4, the cofactor for promoting eNOS coupling, will allow eNOS to increase NO release
while decreasing SO production and subsequent H2O2 release.
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Effects of BH2 on H2O2 and NO Release
We hypothesized that the infusion of BH2 post-ESWL (ESWL + BH2) would
decrease NO release and increase H2O2 release compared to ESWL + saline control or

EWSL + BH4. Administration of BH2, the cofactor for eNOS uncoupling, is assumed to
have the opposite effects of BH4, by promoting more eNOS uncoupling. This in turn
would decrease NO release while inducing eNOS SO production and subsequent H2O2
release.
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Methods
Measurement of NO and H2O2 Release from Left Rat Renal Vein
Each experimental rat was anesthetized with an initial induction dose of sodium
pentobarbital (60mg/kg) with an intraperitoneal (i.p.) injection. A maintenance dose
(30mg/kg) of sodium pentobarbital was given via i.p. injection at approximately 45-

minute intervals unless otherwise required. The rat was also injected i.p. with 1 milliliter
(mL) of sodium heparin (1000 USP units/mL) to prevent blood clotting. The rat’s back
was then covered with Sonotech Litho Clear acoustic transmission gel (Magnaflux,
Bllingham, WA) to ensure constant contact of the animal with the lithotripter via a gel
medium. The rat was placed on a wooden operating sheet, and it’s left kidney was
aligned within the range of the lithotripter’s focal point. Next, the external jugular vein
was exposed and a 24-gauge catheter was inserted for drug or saline infusion after the
ESWL treatment was finished. A mid-line laparotomy was performed on the animal to
isolate the left renal vein. Once exposed, the left renal vein was catherized using a 22gauge angio-catheter (Figure 3).
A NO or H2O2 microsensor (100µm diameter) was inserted through the renal vein
catheter and then connected to the Apollo 4000 Free Radical Analyzer (World Precision
Instruments (WPI), Inc. Sarasota, FL), which provides a real-time measurement tracing
of NO or H2O2 release through an electrical picoamp (pA) response. The microsensor
was supported by gauze and positioned in direct opposition of the blood flow of the left
renal vein. Only the left renal vein can be exposed and isolated for catherization, so only
one microsensor can be used per experiment, hence only NO or H2O2 can be measured at
one time.
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Once the sensor was inserted into the left renal vein via the 22-gauge catheter, a

period of baseline measurements were taken. The tracing was recorded until the baseline
was considered stable, which is when a decrease of 300 picoamps (pAs) every 300
seconds is reached. The final baseline recording served as a “zero” recording and all
measurements taken post-ESWL would be expressed as relative difference compared to
the final baseline measurement as in previous studies (Iames et al. 2011; Chen et al.
2010).
After a stable baseline was established, ESWL treatment was initiated and 1000
shocks were delivered in two different frequency periods. The first 500 shocks was
delivered in a lower frequency period of 60 beats per minute, and the last 500 shocks was
delivered in a higher frequency period of 120 beats per minute. The entire ESWL
treatment was given at an intensity level of 13 (16kV), which is the highest intensity
setting on this lithotripter, and the shockwave treatment lasted approximately 13 minutes.
For the non-ESWL controls, ESWL treatment was never induced and there was a 13minute waiting period of pseudo-ESWL. This protocol was adapted from Weber et al.
(1992), and it was later modified by our research group in Iames et al. (2011) and Chen et
al. (2010).
Immediately after the cessation of ESWL treatment or pseudo-ESWL, 0.5 mL of
saline or saline + drug was infused through the jugular vein canulation, and then another
0.5 mL of saline was infused as a flush. In ESWL + drug experiments, the appropriate
dosage of either BH2 (mol. wt. 239.23)(Cayman Chemicals) or BH4 (mol. wt.
314.2)(Cayman Chemicals) was infused with 0.5 mL of saline. Previous studies have
established the appropriate dosage for each drug, and BH2 is given at 2.0 mg/kg (100 µM
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approximately in blood) and BH4 is given at 6.5 mg/kg (250 µM approximately in blood).
Recordings were taken in pA from the free radical analyzer at the beginning and end of
ESWL treatment and then in five-minute intervals for 30 minutes post-ESWL treatment
as previously described (Iames et al. 2011).

Animal Model
The Institutional Animal Care and Use of Laboratory Animals Committee of the
Philadelphia College of Osteopathic Medicine approved the experimental protocol
preformed in this study. The animals used in all experiments were male Sprague-Dawley
rats (275-325 grams) (Ace Animals, Boyertown, PA).
Experimental Apparatus
A Dornier Epos Ultra HE (high-energy) lithotripter (Dornier MedTech,
Kennesaw, GA) was used to induce the ESWL shockwave treatment. During each
experiment, the free radical tracing was recorded by the Apollo 4000 Free Radical
Analyzer (WPI, Inc.) A NO or H2O2 microsensor (100µm) (WPI, Inc.) was connected to
the free radial analyzer which was linked to a built-in computer, which recorded the NO
or H2O2 tracing, respectively.
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Figure 3. The rat is placed on a board that maintains the left kidney within the focal
point of the shock wave transmitter on the lithotripter’s mechanical arm. The
microsensor is inserted into the left renal vein and supported by gauze in direct
opposition to the renal vein blood flow.
Microsensor Calibration
All NO and H2O2 microsensors were calibrated prior to each experiment to
determine their sensitivity. The microsensor was calibrated in order to calculate a
standard calibration curve, which gave a precise and consistent measurement to translate
data across all experiments. The tracings were recorded on the free radical analyzer from
the electrical response in pA and were translated into molar concentration in vivo using
the standard curve. The standard curve was created by a stepwise dose-response of the
NO or H2O2 microsensor using an appropriate standard solution depending on the type of
sensor being calibrated.
There are no microsensors for SO, so H2O2 will be monitored as an indirect
product of SO. SOD catalyzes the reaction between SO and hydrogen ions, which results
in H2O2, and thus H2O2 indirectly reflects the concentration of SO in the cells/blood. To
calibrate the H2O2 microsensor, the reference tip of the sensor was submerged in 10 mL
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of phosphate buffered saline (PBS 0.01M) until the trace recorded a stable baseline. The
standard 1.0 mM H2O2 solution was prepared in deionized water, and aliquots of 2.5 µL,
5.0 µL, 10.0 µL, and 20.0 µL (250-2,000 nM) were added stepwise to generate the
standard calibration curve for that H2O2 microsensor.
To calibrate the NO microsensors, the reference tip of the sensor was submerged
in 10 mL of 0.2 M copper sulfate (CuSO4) until a stable baseline was registered. The
standard NO solution was prepared, which consisted of 50 mL aqueous solution with
solutes of 1mg ethylene diamine tetraacetic acid and 1.06 mg of S-nitroso-N-acetyl-1,1penicillamine (SNAP). Aliquots of 1.0µL, 5.0µL, 10.0µL, and 20.0µL of SNAP (10-200
nM) were added stepwise in order to record the NO standard calibration curve.

Table 1. Sample Calibration Curve for NO Microsensor.
NO (nM)

Picoamp (pA) response

0

0

6

530.02

30

1755.55

60

3154.86

120

4550.83
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NO (nM)

Picoamp(pA)
Figure 4. Sample Calibration Curve for NO Microsensor.
Experimental Groups
Each experimental group was exposed to the same number, intensity and
frequency of ESWL shockwaves, except the non-ESWL group, which consisted of a 13minute wait period of pseudo-ESWL, which is the time it takes to complete ESWL
treatment.

Table 2. Experimental Groups.
Group
Non-ESWL Control
(No Drug)
ESWL + Saline Control
(1mL 0.9% Saline)
ESWL + BH4
(6.5 mg/kg BH4) (250µM)
ESWL + BH2
(2.0 mg/kg BH2) (100µM)

Nitric Oxide (NO)

Hydrogen Peroxide (H2O2)

n=6

n=5

n=5

n=5

n=5

n=5

n=5

n=5
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Statistical Analysis

All data in the text and figures were presented as means ±SEM. The data for each
recorded time-point were compared using the analysis of variance (ANOVA) using the
post hoc analysis with the Bonferroni/Dunn. Probability values of less than 0.05 (i.e., p<
0.05) were considered to be statistically significant.
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Results
The two graphs in this section are measured as relative changes from baseline,

and baseline is considered to be “zero”. When an experimental group shows a decrease
or increase of NO or H2O2 release, it is signified as a change from zero to a negative or
positive number, respectively.

Figure 5. Effects of BH4 and BH2 on Real-time blood NO release after ESWL.
This graph shows change in NO release in renal blood post-ESWL relative to
baseline. ESWL significantly reduced NO release (by 196.90 nM from baseline)
compared to no-ESWL (**p≤0.01) from 5-30 minutes post-ESWL. ESWL + BH4
group is similar to no-ESWL control. ESWL + BH4 significantly attenuates
decreased NO levels (5-30 min post-ESWL) compared to ESWL + saline groups
(**p≤0.01). ESWL + BH2 group is similar to ESWL+ saline group and reduced NO
release by 242 nM from baseline. There was significant difference between ESWL +
BH4 compared to ESWL + BH2 or ESWL + saline from 5-30 minutes. (**p≤0.01,
compared to ESWL + saline) (#p≤0.05, ##p≤0.01, compared to ESWL+BH2)
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Effects of BH4 and BH2 on Real-time Blood NO release after ESWL
The results in Figure 5 show the relative changes of NO release after ESWL
treatment in the no-ESWL saline control, ESWL-treated saline control, ESWL + BH4

treated group and ESWL + BH2 treated group. The baseline for NO levels for each group
is set at 0 nM and every other time point illustrates either an increase or decrease in NO
release. In this graph, the ESWL + saline control group shows a sustained and
progressive decrease in NO release over 30 minutes post-ESWL. The ESWL + saline
control group showed an average decrease of 196.90 nM NO release over the 30 minute
time period compared to the no-ESWL control group, which only had a decrease in NO
release of 42.94 nM. The infusion of BH2 post-ESWL treatment showed a similar trend
in decreased NO release as the ESWL + saline control group, with an averaged decreased
NO release of 242.34 nM over the 30 minute time period. On the other hand, the infusion
of BH4 post-ESWL follows a similar trend to the no-ESWL saline control group by
attenuating the decrease of NO release. The ESWL + BH4 treated group showed an
averaged decrease in NO release of only 24.53 nM, which was significantly higher
compared to the ESWL-saline or ESWL + BH2 group. Moreover, the ESWL + BH4
group was similar to the no-ESWL control group in renal blood NO release throughout
the experimental protocol.
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Figure 6. Effects of BH4 and BH2 on Real-time blood H2O2 release after ESWL.
This graph shows change in H2O2 release in renal blood post-ESWL relative to
baseline. ESWL significantly increased H2O2 release by 1µM compared to noESWL from 5-30 minutes post-ESWL. The ESWL-induced H2O2 levels were
significantly attenuated by BH4 compared to the saline control group from 10-30
minutes post-ESWL. There was no significant difference in H2O2 levels for ESWL +
BH2 compared to ESWL + saline. There was significant difference of ESWL + BH4
((#p≤0.05) compared to ESWL + BH2 from 15-30 minutes. (*p≤0.05, **p≤0.01,
compared to ESWL + saline) (#p≤0.05, ##p≤0.01, compared to ESWL + BH2)
Effects of BH4 and BH2 on Real-time Blood H2O2 release after ESWL
The results in Figure 6 show the relative changes of H2O2 release in the no-ESWL
saline control, ESWL-treated saline control, ESWL + BH4 treated group and ESWL +
BH2 treated group. The baseline for H2O2 levels for each group is set at 0 µM and every
other time point illustrates either an increase or decrease in H2O2 release. In this graph,
the ESWL + saline control group shows a sustained and progressive increase in H2O2

	
  

30

release compared to the no-ESWL saline control group. The ESWL + saline control
group had increased the level of H2O2 release by 1.02 nM to the no-ESWL saline controls
over the 30 minute time period. The infusion of BH2 post-ESWL shows a similar trend
to the ESWL + saline control group, with an increased level of H2O2 release (0.75 nM)
compared to the no-ESWL control group. Infusion of BH4 post-ESWL did significantly
attenuate the ESWL-induced H2O2 release from the 10-30 minute time points by 0.98µM;
this is a decrease of 0.56 µM compared to the ESWL + saline control group. The
infusion of BH4 did not decrease H2O2 release to the level of no-ESWL controls, so BH4
infusion did not totally negate the effect of ESWL on H2O2. However, the ESWL + BH4
group was not significantly different from the no-ESWL control group.
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Discussion
Summary of Major Findings

The major findings of this study conclude the results found in the comparison of
the no-ESWL control group to the ESWL-saline control group and also between the
ESWL-saline control group and the ESWL+ BH4 and ESWL+ BH2 treated groups.
Compared to the no-ESWL control group, the ESWL-saline control group showed
significantly decreased blood NO release and significantly increased blood H2O2 release
after ESWL therapy. This supports our first hypothesis that ESWL treatment causes
oxidative stress, such as increased oxidative stress (i.e. H2O2) and also causes reduced
NO bioavailability. The results of the ESWL+BH4 treated group are similar to the noESWL control group, which may be due to promoting eNOS coupling. Lastly, the
ESWL +BH2 treated group is similar to the ESWL-saline control group and further
confirms our hypothesis that BH4 would attenuate ESWL-induced oxidative stress and
decreased NO bioavailability. However, we hypothesized that BH2 would exacerbate
ESWL-induced oxidative stress and it only remained similar to ESWL + saline control.
We speculate that this maybe due to high levels of BH2 already generated by ESWL that
produced saturation of eNOS binding conditions.
Effect of ESWL Treatment of Normal Renal Vein NO and H2O2 Release
The results from ESWL on NO and H2O2 blood levels confirmed the increased
oxidative stress on the kidney vasculature after ESWL treatment. This study showed that
ESWL results in increased oxygen free radicals, such as SO, which is then further
converted to H2O2 by superoxide dismutase. Levels of H2O2 release were significantly
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increased during the entire 30-mintue time period post-ESWL compared to no-ESWL
saline control group, and NO levels were significantly decreased compared to the same
group during the 30-mintues post-ESWL. Even taking into account the new protocols for
ESWL to limit the damage to the kidney, oxidative stress to the kidney vasculature may
still occur after treatment. These changes in NO and H2O2 release levels are
characteristic of an I/R injury that leads to vascular endothelial dysfunction. Although
ESWL produces more of a pseudo-I/R injury because the kidney does not undergo
complete loss of blood perfusion during the treatment, the results of ESWL on NO and
H2O2 levels are very similar to a true I/R injury. As seen in a study by Parker et al. in
2012 that induced a true I/R injury using femoral artery clamping and subsequent release
in a rat model, blood levels of NO and H2O2 decreased and increased, respectively,
compared to the sham limb that did not undergo femoral artery clamping (Parker et al.
2012). The increased oxidative stress and reduced NO bioavailability caused by ESWL
treatment are characteristic of endothelial dysfunction, which characterizes many
vascular disease states, such as diabetes, atherosclerosis and mainly in the kidney,
hypertension (Channon 2004). A 19 year follow up study by Krambeck et al. in 2006
showed a correlation between patients treated with ESWL for renal and proximal ureteral
stones and the development of diabetes mellitus and hypertension. The development of
diabetes mellitus was related to the number of shockwaves delivered and the intensity of
the ESWL treatment. Furthermore, cases of hypertension were significantly higher in
patients treated with ESWL compared to that in patients treated conservatively with
stones, and they suggest that damage to the renal parenchyma and vasculature contributes
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to the development of hypertension in these patients. Lastly, the study shows that this

effect was exacerbated in patients with bilateral ESWL treatments (Krambeck et al. 2006)
Effect of BH4 on NO and H2O2 release levels after ESWL treatment
This study shows that supplementation with BH4 can attenuate the oxidative stress
that is caused by ESWL treatment. The results conclude that supplementation with BH4
was able to attenuate the reduced NO bioavailability caused by ESWL immediately after
5 mins post-ESWL and lasts for 30 minutes following treatment. Furthermore, the results
show that giving BH4 after ESWL leads to normal basal levels of NO that are similar to
no-ESWL treatment. Moreover, after 5 minutes post-ESWL, the NO release level starts
to increase compared to the no-ESWL control. This shows that supplementation with
BH4 increases the BH4 to BH2 cofactor ratio to favor eNOS coupling activity to produce
more NO, and it gives protection against reduced NO bioavailability caused by ESWL.
This study also shows that giving BH4 will reduce H2O2 levels after 10 minutes
post-ESWL. Again, the BH4 treated group is similar to the no-ESWL control in terms of
significantly decreased H2O2 release levels during the 30 minute post-ESWL time line
compared to ESWL + saline group. However, the no-ESWL group displayed the greatest
drop in H2O2 release among the four study groups. Two possible causes of this could be
that 1) eNOS was saturated with BH4 and/or 2) there was too much SO produced during
the ESWL treatment that it was quenching the NO produced by coupled eNOS to produce
ONOO- anion that was causing some residual oxidative stress, hence more elevated H2O2
levels compared to no-ESWL. These results show that supplementation with BH4 after
ESWL treatment is entirely protective in terms of attenuating the decreased NO caused
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by ESWL, but it is only partially protective in decreasing the H2O2 release to the level of
the no-ESWL control group.
Effect of BH2 on NO and H2O2 release levels after ESWL treatment
This study shows that supplementation with BH2 can maintain and further add to
the oxidative stress that is caused by ESWL treatment. The data shows that the BH2treated group is similar to the ESWL-saline control group. In terms of NO and H2O2
release post-ESWL, the results conclude that supplementation with BH2 decreased NO
release levels compared to the BH4 or no-ESWL groups and suggests that BH2
maintained increased oxidative stress and decreased NO bioavailability due to ESWLinduced eNOS uncoupling. Because ESWL leads to oxidative stress, the oxidative stress
is known to oxidize BH4 to BH2, which then increases the BH2 to BH4 cofactor ratio and
BH2 becomes the eNOS cofactor. In this situation, eNOS uncoupling activity is
promoted and more SO is produced to quench NO bioavailability.
This study also shows that supplementation with BH2 is similar to the ESWLsaline control group in terms of H2O2 release. On the other hand, the BH2 treated group
did not show as drastic an increase in H2O2 as the ESWL-saline group as we had
expected. Two possible causes of this could be that 1) the dosage of BH2 is not high
enough, which could be examined in future studies and/or 2) that the eNOS was already
saturated with the BH2 cofactor and that it couldn’t produce more H2O2.
Limitations
One of the main limitations to this study was the rat models subjected to the
ESWL procedure did not have kidney stones, unlike in true clinical settings where the
patients receiving the ESWL treatment do have kidney stones. Therefore, we were
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unable to access how the presence of a kidney stone would affect the oxidative stress
cause by ESWL. It could be speculated that a kidney stone could absorb some of the

damaging shock waves and therefore, may be less invasive than in the non-kidney stone
rat model that we used in this study.
Future Studies
One of the reasons that BH4 has limited utility on H2O2 in the setting of an I/R
injury may be that the higher doses are not effective due to the oxygenase domain of
eNOS being at saturated conditions with BH4. A promising alternative to overcome this
situation is to enhance eNOS activity, using PKC-ε activator, along with BH4 to promote
eNOS coupling to increase NO release during reperfusion (Perkins et al. 2012).
Furthermore, it has been shown in a hind limb I/R model that PKC-ε inhibitor
significantly reduced H2O2 release, which suggests that the attenuation of eNOS activity
is associated with reduced oxidative stress (Teng et al. 2008). The major findings of a
study using a hind limb I/R model with supplementation of PKC-ε activator/inhibitor and
BH4/BH2 are significant to this ESWL model and should be implemented into the future
studies of this project. The findings of the hind limb I/R model were that treatment with
PKC-ε activator + BH4 was associated with a significant increase in NO release and
decrease in H2O2 release, which supports the hypothesis that promoting eNOS coupling
(i.e. BH4) combined with an eNOS activity enhancer (i.e. PKC-ε activator) would
attenuate oxidative stress from an I/R injury (Perkins et al. 2012). Furthermore, groups
treated with PKC-ε activator + BH2 were associated with increased H2O2 and decreased
NO release, and were shown to exacerbate the oxidative stress. Lastly, all PKC-ε
inhibitor groups treated with either BH4 or BH2 decreased H2O2 release and increased NO
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release in hind limb I/R. This is because PKC-ε inhibitor decreased eNOS activity in its
uncoupled state, therefore H2O2 release is decreased and also, it reduces the quenching of
NO by SO, which subsequently increases NO bioavailability (Perkins et al. 2012). The
future research of this project will be directed towards investigating the effects of
treatment with all combinations of PKC-ε activator/inhibitor and BH4/BH2 to attenuate
the ESWL-induced oxidative stress in this model. Furthermore, plasma samples were
collected from post-ESWL-treated and non-ESWL treated rats, and in a future study
these samples can be evaluated to determine the concentration ratio of BH4:BH2 in
ESWL-treated and non-treated plasma.
Significance of Findings
Until the technology improves or another method for targeting kidney stones is
developed, treatment for the damage caused by ESWL treatment must focus on
improving the technique of ESWL delivery or pharmacological invention. Although
there is new research on improving ESWL delivery protocols to minimize the damage,
there is still a lack of research conducted on the ESWL-induced oxidative stress that leads
to vascular endothelial disease states, such as acute to chronic hypertension. This study
confirms that even under the safer ESWL procedures, the blood levels of H2O2 and NO
release indicate increased oxidative stress and reduced NO bioavailability post-ESWL
treatment, which are both major characteristics of endothelial dysfunction. Our research
has also found that eNOS is the principal target responsible for oxidative stress after
lithotripsy as BH4 is oxidized to BH2. The data from this study suggests that the
beneficial effects of BH4, such as increased NO release, may be due to the increased BH4
to BH2 ratio, which promotes coupled eNOS. Furthermore, our data suggests that

	
  

37

supplementation of BH2 reverses this ratio in favor of BH2 to promote uncoupled eNOS
with the further production of SO, which is the primary source of oxidative stress postESWL. In conclusion, this study suggests that supplementation of BH4 after ESWL
treatment could increase NO bioavailability and reduce oxidative stress to attenuate
endothelial dysfunction to the renal vasculature to avoid the development of hypertension
clinically.
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